United States - English - NLM (National Library of Medicine)

a2a integrated pharmaceuticals - selegiline hydrochloride (unii: 6w731x367q) (selegiline - unii:2k1v7gp655) - selegiline hydrochloride tablets, usp are indicated as an adjunct in the management of parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. there is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of ‘off’ time and patient self-rating of treatment success. beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and comparison to previous state). selegiline hydrochloride is contraindicated in patients with a known hypersensitivity to this drug. selegiline is contraindicated for use with meperidine. this contraindication is often extended to other opioids. (see drug interactions .)

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - selegiline hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

orion pharma (aus) pty limited - selegiline hydrochloride, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; maize starch; microcrystalline cellulose; mannitol - as an adjunct in the management of late stage parkinson's disease in patients being treated with levodopa and/or a peripheral decarboxylase inhibitor, who exhibit deterioration in the quality of their response to the therapy. indications as approved 22 january 1999 - eldepryl is indicated for the treatment of patients with parkinson's disease. it can be used as monotherapy in the early phases of the disease and as adjunctive therapy with levodopa (with/without a peripheral decarboxylase inhibitor) as an adjunct in the management of late stage parkinson's disease in patients being treated with levodopa and/or a peripheral decarboxylase inhibitor, who exhibit deterioration in the quality of their response to the therapy. indications as approved 22 january 1999 - eldepryl is indicated for the treatment of patients with parkinson's disease. it can be used as monotherapy in the early phases of the disease and as adjunctive therapy with levodopa (with/without a peripheral decarboxylase inhibitor)

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - selegiline hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - selegiline hydrochloride -

United States - English - NLM (National Library of Medicine)

bausch health us, llc - selegiline hydrochloride (unii: 6w731x367q) (selegiline - unii:2k1v7gp655) - selegiline hydrochloride 1.25 mg - zelapar is indicated as an adjunct in the management of patients with parkinson’s disease being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. there is no evidence from controlled studies that zelapar has any beneficial effect in the absence of concurrent levodopa therapy [see clinical studies (14) ]. zelapar is contraindicated in patients with: risk summary there are no adequate data on the developmental risk associated with the use of zelapar in pregnant women. in animal studies, administration of selegiline during pregnancy was associated with developmental toxicity (decreased embryofetal and postnatal offspring growth and survival) at doses greater than those used clinically. in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage in the indicated population is u

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - selegiline hydrochloride (unii: 6w731x367q) (selegiline - unii:2k1v7gp655) - selegiline hydrochloride 5 mg

United States - English - NLM (National Library of Medicine)

rising pharma holdings, inc. - selegiline hydrochloride (unii: 6w731x367q) (selegiline - unii:2k1v7gp655) - selegiline capsules, usp are indicated as an adjunct in the management of parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. there is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of ‘off’ time, and patient self-rating of treatment success. beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and co

United States - English - NLM (National Library of Medicine)

proficient rx lp - selegiline hydrochloride (unii: 6w731x367q) (selegiline - unii:2k1v7gp655) - selegiline capsules, usp are indicated as an adjunct in the management of parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. there is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of ‘off’ time, and patient self-rating of treatment success. beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and co

Canada - English - Health Canada

teva canada limited - selegiline hydrochloride - tablet - 5mg - selegiline hydrochloride 5mg - monoamine oxidase b inhibitors